Malaysia Blood Plasma Market, By Type (Hyperimmune Globulin, Albumin, Factor VIII, Factor IX, Immunoglobulin, Others), Mode of Delivery (Infusion Solutions, Gels, Sprays, Biomedical Sealants), Therapeutic Indication (Immunology, Oncology, Pulmonology, Rheumatology, Transplantation, Neurology, Hematology, Other), Application (Hypogammaglobulinemia, Immunodeficiency Diseases, Hemophilia, Von Willebrand's Disease (vWD), Others), End-User (Clinics, Hospitals, Other) - Industry Trends and Forecast to 2030.
Malaysia Blood Plasma Market Analysis and Size:
The increasing demand for plasma-derived medicines acts as one of the major factors driving the growth of blood plasma market. The advancements in medical technology and increasing health care infrastructure expenditure accelerate the blood plasma market growth.
Data Bridge Market Research analyses that the Malaysia blood plasma market which was USD 3,372 million in 2022, is expected to reach USD 6,521 million by 2030, and is expected to undergo a CAGR of 4.20 % during the forecast period. This indicates that the hyperimmune globulin segment dominates the type segment of the blood plasma market owing to the advancements in technology have led to the development of advancements in blood plasma products for various use. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Malaysia Blood Plasma Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Type (Hyperimmune Globulin, Albumin, Factor VIII, Factor IX, Immunoglobulin, Others), Mode of Delivery (Infusion Solutions, Gels, Sprays, Biomedical Sealants), Therapeutic Indication (Immunology, Oncology, Pulmonology, Rheumatology, Transplantation, Neurology, Hematology, Other), Application (Hypogammaglobulinemia, Immunodeficiency Diseases, Hemophilia, Von Willebrand's Disease (vWD), Others), End-User (Clinics, Hospitals, Other)
|
|
Countries Covered
|
U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
|
|
Market Players Covered
|
CSL Limited (Australia), Grifols, S.A.(Spain), Takeda Pharmaceutical Company Limited (Japan) and Octapharma AG (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
It refers to the market for the collection, processing, and distribution of blood plasma in Malaysia. Blood plasma is the yellowish liquid component of blood that remains after red blood cells, white blood cells, platelets, and other cellular components have been removed. It plays a crucial role in maintaining overall health and contains various proteins, antibodies, clotting factors, and nutrients.
Malaysia Blood Plasma Market Dynamics
Drivers
- Increasing Prevalence of Chronic Diseases
The rising incidence of chronic diseases such as cancer, autoimmune disorders, and hemophilia drives the demand for blood plasma-based therapies. Plasma-derived products such as immunoglobulins, clotting factors, and albumin are essential for the treatment of these conditions
- Growing Aging Population
Malaysia, such as many other countries, has a growing aging population. Elderly individuals are more susceptible to various health conditions, including immune disorders and coagulation disorders. The need for blood plasma-based therapies increases with the aging population, thereby driving the market growth
- Technological Advancements
Advances in technology have significantly improved the collection, processing, and storage of blood plasma. Automation, better testing methods, and increased efficiency in plasma fractionation processes have made plasma-derived products more accessible and reliable, driving market growth
Opportunities
- Increased Awareness and Screening for Blood-Related Diseases
Awareness campaigns, public health initiatives, and increased screening for blood-borne diseases have led to the identification of more individuals who require plasma-based therapies. This has created a larger patient pool and subsequently increased the demand for blood plasma products
- Government Support and Regulations
The Malaysian government plays a crucial role in regulating and promoting the blood plasma market. Favorable policies, regulations, and support for the development and distribution of plasma-derived products encourage market growth and investment in the sector
Restraints/Challenges
- Regulatory Challenges
The blood plasma market is subject to stringent regulations and guidelines to ensure the safety and quality of the collected plasma. Compliance with these regulations can pose challenges for market participants, including obtaining necessary approvals, meeting quality standards, and adhering to safety protocols
- Limited Donor Pool
The availability of suitable blood plasma donors can be a restraint. The eligibility criteria for plasma donation can be quite restrictive, including factors such as age, health conditions, and previous medical history. This limited pool of eligible donors may impact the overall supply of blood plasma in the market
This Malaysia blood plasma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Recent Developments
- In May 2023, Teva Pharmaceutical Industries Ltd. announced a new strategic framework with four main pillars to position the Company for a new era of growth. This strategy aims to bolster the Company’s strong commercial portfolio with AUSTEDO®, AJOVY®,UZEDYTM and biosimilars, amplify its innovative pipeline, sustain its generics powerhouse and focus the business
- In November 2022, A wholly-owned subsidiary of Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) and Sun Pharma Advanced Research Company Ltd
Malaysia Blood Plasma Market scope
The Malaysia blood plasma market is segmented on the basis of type, mode of delivery, therapeutic indication, application, and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Hyperimmune Globulin
- Albumin
- Factor VIII
- Factor IX
- Immunoglobulin
- Others
Mode of Delivery
- Infusion Solutions
- Gels
- Sprays
- Biomedical Sealants
Therapeutic Indication
- Immunology
- Oncology
- Pulmonology
- Rheumatology
- Transplantation
- Neurology
- Hematology
- Other
Application
- Hypogammaglobulinemia
- Immunodeficiency Diseases
- Hemophilia
- Von Willebrand's Disease (vWD)
- Others
End-User
- Clinics
- Hospitals
- Other
Competitive Landscape and Malaysia Blood Plasma Market Share Analysis
The Malaysia blood plasma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Malaysia blood plasma market.
Some of the major players operating in the Malaysia blood plasma market are
- CSL Limited (Australia)
- Grifols, S.A.(Spain)
- Takeda Pharmaceutical Company Limited (Japan)
- Octapharma AG (Switzerland)
SKU-